Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

September 8, 2020

- **FIRST ALLOGENEIC CAR-T CELL THERAPY WITH PD-1 DELETED BY CRISPR GENOME EDITING CLEARED FOR PHASE 1 CLINICAL TRIALS**
- **UPON INITIATION OF THE ANTLER PHASE 1 CLINICAL TRIAL, CB-010 WILL BE CARIBOU'S FIRST CLINICAL-STAGE PRODUCT CANDIDATE**

Berkeley, CA — Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CB-010, an off-the-shelf allogeneic anti-CD19, genome-edited CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL).

Upon initiation of the ANTLER Phase 1 trial, CB-010 will be Caribou's first clinical-stage product candidate. CB-010 is manufactured from healthy donor T cells using Caribou's next-generation CRISPR genome editing technology. Through genome editing, PD-1 is deleted from the CAR-T cells, which in preclinical studies promoted an increase in the durability of antitumor activity. Genome editing is used to remove the endogenous T cell receptor in order to prevent graft-versus-host disease and to site-specifically insert the CAR into the CAR-T genome.

"We are excited to receive clearance for our first IND, a pivotal milestone in the continued evolution of Caribou," said Rachel Haurwitz, Ph.D., Caribou's President and Chief Executive Officer. "Caribou's genome-edited cell therapies hold tremendous potential for patients and we are eager to begin clinical studies for CB-010."

ANTLER is an open-label study designed to evaluate the safety and efficacy of a single dose of CB-010 in adult patients with different subtypes of relapsed/refractory B-NHL. The study will be conducted at multiple clinical trial sites in the United States, and enrollment is expected to begin later this year.

"B-NHL comprises multiple serious and life-threatening diseases, and CB-010 therapy has the potential to extend lives," said Steve Kanner, Ph.D., Caribou's Chief Scientific Officer. "CB-010 is distinct among allogeneic CAR-Ts since the critical checkpoint PD-1 is eliminated to reduce CAR-T cell exhaustion, which we believe offers a crucial therapeutic advantage."

About Caribou Biosciences, Inc.

Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company is developing an internal pipeline of off-the-shelf allogeneic CAR-T cell therapies and genome-edited natural killer (NK) cell therapies. For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio.

Caribou Biosciences Media Contact:

Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
617-461-4023